Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 10

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
 settlement, the Company received an upfront payment of $26.0 million and will receive royalties on Vizgen’s sales of products covered by the license. The $26.0 million upfront payment was recorded as a $9.2 million gain on settlement and $16.8 million of license and royalty revenue. The amount attributed to the gain on settlement was determined by applying a royalty rate to the Vizgen historical revenues prior to the settlement.Other Income (Expense), NetGains or losses from foreign currency remeasurement are included in “Other income (expense), net” in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $1.5 million for the three months ended March 31, 2025, and foreign currency transaction income of $1.0 million for the three months ended March 31, 2024, respectively.

4.    Commitments and Contingencies

Lease AgreementsThe Company leases office, laboratory, manufacturing, distribution and server space in various locations worldwide. The payments due under the Company’s operating lease liabilities as of March 31, 2025 are as follows (in thousands):Operating Leases2025 (excluding the three months ended March 31, 2025)$10,101 202615,371 202715,585 202815,756 202914,329 Thereafter26,339 Total lease payments$97,481 Less: imputed interest(17,407)Present value of operating lease liabilities$80,074 Operating lease liabilities, current$9,443 Operating lease liabilities, noncurrent70,631 Total operating lease liabilities$80,074 The following table summarizes additional information related to operating leases as of March 31, 2025:March 31,2025December 31, 2024Weighted-average remaining lease term6.6 years6.8 yearsWeighted-average discount rate5.8 %5.8 %LitigationThe Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. As of March 31, 2025, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.

13

Table of Contents10x Gen